Cephalexin

Autoimmune Diseases

Mayo ClinicSmall moleculePhase 4 / ApprovedActive

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 81/ 100

Competitive context

26 Active assets in the Autoimmune Diseases cohort.

Asset / Sponsor	Phase	Rating
total glucosides of paeony West China Hospital	Phase 4	BB
URSODEOXYCHOLIC ACID West China Hospital	Phase 4	BB
Cyclophosphamide The Children's Hospital of Zhejiang University School of Medicine	Phase 2	B
CEFADROXIL ANHYDROUS Mayo Clinic	Phase 4	B
Doxycycline Mayo Clinic	Phase 4	B

View all 35 →

Same molecule, other indications

Cephalexin is also rated in:

periprosthetic joint infectionDormant

BB

Indicative ·

65 / 100

methicillin-susceptible staphylococcus aureus infectious diseaseDormant

BB

Indicative ·

65 / 100

methicillin-resistant staphylococcus aureus infectious diseaseDormant

BB

Indicative ·

65 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.